specific capsular substance

(redirected from pneumococcal polysaccharide)

spe·cif·ic cap·su·lar sub·stance

a soluble type-specific polysaccharide produced during active growth of virulent pneumococci comprising a large part of the capsule.
Mentioned in ?
References in periodicals archive ?
Pneumococcal vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) based on shared clinical decision making is recommended for immunocompetent adults aged 65 years and older who have not previously received PCV13, and all adults aged 65 years and older should continue to receive the pneumococcal polysaccharide vaccine (PPSV23), according to a vote at a meeting of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.
They also recommend the pneumococcal polysaccharide vaccine for all adults 65 years or older, people 2 through 64 years old with certain medical conditions, and adults 19 through 64 years old who smoke cigarettes.
The pivotal Phase 3 trial is enrolling an estimated 3,880 adults and is designed to compare immune responses after 20vPnC administration to responses in control subjects >=60 years old receiving 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine; evaluate the immunogenicity of 20vPnC in adults 18-59 years of age; and describe the 20vPnC safety profile in adults >=18 years old.
This first Phase 3 trial will enroll an estimated 3,880 adults and is designed to compare immune responses after 20vPnC administration to responses in control subjects greater than or equal to60 years old receiving 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine; evaluate the immunogenicity of 20vPnC in adults 18-59 years of age; and describe the 20vPnC safety profile in adults greater than or equal to18 years old.
There are two pneumonia vaccines: Pneumococcal Conjugate Vaccine, and PCV13 (Prevnar), and Pneumococcal Polysaccharide Vaccine, or PPSV23 (Pneumovax).
Food and Drug Administration licensed two vaccines: pneumococcal polysaccharide (PPSV23) and 13 valent pneumococcal conjugate (Prevnar 13[R]) [PCV13].
"The currently recommended prime-boost vaccination strategy using a dose of PCV13 [13-valent pneumococcal conjugate vaccine] followed by a dose of PPV23 [23-valent pneumococcal polysaccharide vaccine] might be a possible way of enhancing the vaccine immunogenicity in immuno-suppressed patients," Dr.
Furthermore, we observed the emergence of 35B-CC156 after introduction of PCV13 and noted that 35B-CC156 isolates were multidrug-resistant (penicillin nonsusceptibility plus resistance to [greater than or equal to] 2 non-[beta]-lactam antimicrobial drugs), similar to previous observations of CC156 associated with other pneumococcal polysaccharide capsules (e.g., serotypes 9V and 14).
* Pneumococcal: One dose each of the pneumococcal conjugate vaccine and the pneumococcal polysaccharide vaccine, given a year apart, for everyone age 65 or older.
On September 19, 2014, CDC published the Advisory Committee on Immunization Practices (ACIP) recommendation for the routine use of 13-valent pneumococcal conjugate vaccine (PCV13) among adults aged [greater than or equal to] 65 years, to be used in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23) (1).
Additionally, PCV13 and the pneumococcal polysaccharide vaccine (PPSV23) should not be administered together.

Full browser ?